These findings show that inflammatory cytokines, especially the IL-6 family, may be novel biological therapeutic targets for the treatment of type 2 diabetes and metabolic disorders, even when its safety for inflammation is guaranteed. This evidence concerns the gene IL6 and metabolic disease.